金城医药(300233) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥953,062,199.12, representing a 56.50% increase compared to ¥608,977,257.17 in the same period last year[10] - Net profit attributable to shareholders for Q1 2022 was ¥112,478,901.17, a significant increase of 121.18% from ¥50,855,115.49 in the previous year[10] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥109,032,761.00, reflecting a 169.22% increase from ¥40,499,938.16 year-on-year[10] - The company's basic earnings per share for Q1 2022 was ¥0.29, up 123.08% from ¥0.13 in the same quarter last year[10] - The net profit for the current period is 116,066,574.08, a significant increase from 52,846,955.50 in the previous period, representing a growth of approximately 119.8%[48] - The total profit for the current period is 144,236,962.95, compared to 66,708,020.64 in the previous period, indicating an increase of about 116.1%[48] - The operating profit for the current period is 145,165,251.95, up from 68,311,968.89 in the previous period, reflecting a growth of approximately 112.5%[48] - The basic and diluted earnings per share for the current period are both 0.29, compared to 0.13 in the previous period, marking an increase of 123.1%[48] Assets and Liabilities - The total assets at the end of Q1 2022 were ¥5,447,487,026.78, an increase of 3.27% from ¥5,275,153,179.53 at the end of the previous year[12] - Current liabilities totaled ¥1,421,009,274.36, slightly up from ¥1,416,441,979.04, showing a marginal increase of about 0.2%[38] - Non-current liabilities increased to ¥470,766,245.52 from ¥419,289,380.72, representing a growth of approximately 12.3%[38] - The company's cash and cash equivalents at the end of the reporting period amount to ¥933,883,542.38, a decrease from ¥981,084,481.31 at the beginning of the year[32] - The company's total assets rose to ¥5,447,487,026.78, compared to ¥5,275,153,179.53, marking an increase of about 3.3%[41] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥45,797,444.13, a decline of 741.01% compared to a net inflow of ¥7,144,592.39 in the same period last year[23] - Cash flow from operating activities for the current period is -45,797,444.13, a decline from 7,144,592.39 in the previous period[52] - Cash flow from investing activities shows a net outflow of -89,022,464.34, compared to -104,851,243.41 in the previous period, indicating an improvement[52] - Cash flow from financing activities results in a net inflow of 57,004,584.62, down from 73,393,829.77 in the previous period[55] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,778[25] - The largest shareholder, Zibo Jincheng Industrial Investment Co., Ltd., holds 20.28% of shares, totaling 78,552,154 shares[25] - The second-largest shareholder, the National Social Security Fund 115 Portfolio, holds 2.84% of shares, totaling 11,000,000 shares[25] - The company has a total of 22,550,274 shares under lock-up agreements, with specific shares set to be released after certain conditions are met[31] Revenue Drivers and Costs - The increase in revenue was primarily driven by the addition of CMO business and growth in sales of cephalosporin products and other pharmaceutical chemicals[16] - Total operating revenue for the current period reached ¥953,062,199.12, a significant increase from ¥608,977,257.17 in the previous period, representing a growth of approximately 56.5%[42] - Total operating costs amounted to ¥810,774,617.57, up from ¥560,141,656.88, indicating an increase of about 44.6%[42] Other Financial Metrics - The company's weighted average return on equity for Q1 2022 was 3.26%, an increase of 1.79% from 1.47% in the same period last year[10] - The company reported a decrease in government subsidies received, with other income dropping by 66.96% to ¥4,948,549.71 compared to the previous year[21] - The company's financial expenses surged by 1,811.90% to ¥4,222,427.29 due to increased exchange losses during the reporting period[21] Research and Development - Research and development expenses for the current period were ¥43,235,054.66, compared to ¥40,366,166.87 in the previous period, reflecting an increase of about 4.6%[42] Inventory and Receivables - Accounts receivable increased to ¥671,368,826.73 from ¥597,999,093.92 at the beginning of the year[32] - The company reported a significant increase in receivables financing, rising to ¥149,282,243.51 from ¥86,000,989.82[32] - Inventory decreased slightly to ¥385,470,403.98 from ¥391,322,226.99, indicating a reduction of approximately 1.9%[35] - The company's cash and cash equivalents were not detailed, but other receivables increased to ¥12,644,912.81 from ¥8,387,712.18, a rise of about 50.8%[35] Future Outlook - The company has not disclosed any new product developments or market expansion strategies in the current report[30] - There are no new mergers or acquisitions reported in the current financial disclosures[30] - The company has not provided specific future performance guidance in the current report[30]